Davis Polk advised the joint book-running managers in the offering.Adamas Pharmaceuticals, Inc. executed its $59 million follow-on offering of 14,375,000 shares of common stock, which included shares…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now